Pediatric Asthma Treatment Market Size to Reach $14.39 Billion by 2029 | Growth at 5.4% CAGR Forecast

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What is the Projected Market Size of the Pediatric Asthma Treatment Industry?
The size of the pediatric asthma treatment market has experienced robust growth over recent years, expanding from $11.03 billion in 2024, to $11.65 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.6%. This upward trend during the historic phase is largely due to a surge in cases of asthma in children, heightened awareness about children's respiratory problems, an escalation in air contaminants and environmental allergens, an increase in healthcare spending on pediatric care, and concerted efforts by NGOs and healthcare entities to boost understanding of asthma.

What Will Be the Size of the Pediatric Asthma Treatment Market by 2029?
In the coming years, the pediatric asthma treatment market is anticipated to witness robust growth, with its size projected to hit $14.39 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this growth during the forecast period include an increasing number of children suffering from allergic disorders, the wide expansion of biologic therapies tailored for severe pediatric asthma, an upsurge in investments dedicated to pediatric drug development, the growing focus on personalized and precision medicine, and an increasing middle-class populace who have access to private healthcare facilities. Key trends expected during this forecast period are the evolution of pediatric-friendly biologic therapies, the advancement of quick allergen identification methodologies, the incorporation of electronic health records, breakthroughs in inhaler formulation, and innovation in asthma immunotherapy.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/pediatric-asthma-treatment-global-market-report

What Are the Key Drivers Accelerating Growth in the Pediatric Asthma Treatment Market?
The escalating rate of respiratory infections is projected to be a significant driver for the expansion of the pediatric asthma treatment market. Respiratory infections are illnesses caused by various pathogens involving viruses, bacteria, and more, affecting the respiratory tract which encompasses the nose, throat, airways, and lungs. The main culprit for the gradual increase in respiratory infections is the rise in air pollution; exposure to pollutants such as particulate matter and nitrogen dioxide have detrimental effects on the respiratory system, making individuals more likely to contract infections. Pediatric asthma treatment effectively decrease the instances and gravity of respiratory infections by enhancing airway function and suppressing inflammation, leading to a decrease in susceptibility to infectious triggers. To illustrate, as per the Australian Institute of Health and Welfare, a governmental agency based in Australia, chronic obstructive pulmonary disease was responsible for 3.6% of the total disease burden in June 2024 and accounted for 50% of the overall toll from respiratory conditions reported in 2023. Furthermore, in 2022, approximately 638,000 individuals, which equates to 2.5% of Australia's population, were diagnosed with chronic obstructive pulmonary disease. As such, the continual rise in respiratory infections is a major factor driving the growth of the pediatric asthma treatment market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25868&type=smp

How Is the Pediatric Asthma Treatment Market Segmented by Type, Application, and Region?
The pediatric asthma treatment market covered in this report is segmented -

1) By Type: Long-Term Control Medications, Quick-Relief Medications, Other Types
2) By Drug Class: Inhaled Corticosteroids, Long-Acting Beta Agonists, Leukotriene Modifiers, Antihistamines, Biologics
3) By Route Of Administration: Oral Route, Nasal Route, Injectable Route
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Clinics, Home Care, Other End users

Subsegments:
1) By Long-Term Control Medications: Inhaled Corticosteroids, Leukotriene Modifiers, Long-Acting Beta Agonists, Combination Inhalers, Biologic Therapies
2) By Quick-Relief Medications: Short-Acting Beta Agonists, Anticholinergics, Systemic Corticosteroids
3) By Other Types: Immunotherapy, Methylxanthines, Alternative Therapies

What Are the Key Trends Driving Growth in the Pediatric Asthma Treatment Market?
Large firms in the pediatric asthma treatment market are concentrating on the development of innovative interventions such as monoclonal antibodies to curtail airway inflammation in children. These antibodies are artificially created proteins that are designed to imitate the immune system's combat against harmful pathogens by pinpointing and attacking certain cells or substances. For example, AstraZeneca PLC, a pharmaceutical and biotechnology company located in the UK, was granted approval by the U.S. Food and Drug Administration in April 2024 for its product, FASENRA (benralizumab). This product functions as an additional maintenance treatment for severe asthma in children between the ages of 6 and 11, specifically those characterized by an eosinophilic phenotype. This antibody works by targeting and obliterating eosinophils, thus reducing asthma attacks and augmenting symptom control. Fasenra is to be administered subcutaneously once every four weeks for the initial three doses and then once every 8 weeks thereafter, with the pediatric dose being calibrated based on the child's weight.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25868&type=smp

Who Are the Leading Companies Driving Growth in the Pediatric Asthma Treatment Market?
Major companies operating in the pediatric asthma treatment market are Pfizer Inc., Merck And Co Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Genentech Inc., Chiesi Farmaceutici S.p.A, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Lupin Limited, Zydus Lifesciences Ltd., ECU Health.

Which Is the Leading Region in the Global Pediatric Asthma Treatment Market?
North America was the largest region in the pediatric asthma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric asthma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.